These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 32676823

  • 1. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N, Keefe C, Tian C, Hornung L, Khoury J, Tilden JC, Hochwalt P, Jackson E, Rybalsky I, Wong BL, Rutter MM.
    Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
    [Abstract] [Full Text] [Related]

  • 2. Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report.
    Catalano A, Vita GL, Russo M, Vita G, Lasco A, Morabito N, Messina S.
    Osteoporos Int; 2016 Dec; 27(12):3655-3659. PubMed ID: 27589974
    [Abstract] [Full Text] [Related]

  • 3. The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
    Nasomyont N, Tian C, Hornung L, Khoury J, Hochwalt PM, Tilden JC, Wong BL, Rutter MM.
    Muscle Nerve; 2021 Dec; 64(6):710-716. PubMed ID: 34506040
    [Abstract] [Full Text] [Related]

  • 4. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC, Rutter MM.
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [Abstract] [Full Text] [Related]

  • 5. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 6. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M, Quinlivan R, Tirupathi S, Blackwood B.
    Cochrane Database Syst Rev; 2017 Jan 24; 1(1):CD010899. PubMed ID: 28117876
    [Abstract] [Full Text] [Related]

  • 7. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov 24; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
    Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H.
    Clin Interv Aging; 2016 Nov 24; 11():1653-1659. PubMed ID: 27895472
    [Abstract] [Full Text] [Related]

  • 9. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L, Zhou H, Xu H, Sun X, Chen X, Fan P, Cai X, Wang Q.
    Osteoporos Int; 2024 Jun 24; 35(6):997-1005. PubMed ID: 38277031
    [Abstract] [Full Text] [Related]

  • 10. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB, Dai Y, Hu J, Zhao DC, Wang O, Jiang Y, Xia WB, Xing XP, Li M.
    Endocr Pract; 2020 Dec 24; 26(12):1477-1485. PubMed ID: 33471740
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report.
    Kumaki D, Nakamura Y, Sakai N, Kosho T, Nakamura A, Hirabayashi S, Suzuki T, Kamimura M, Kato H.
    JBJS Case Connect; 2018 Dec 24; 8(2):e22. PubMed ID: 29642113
    [Abstract] [Full Text] [Related]

  • 12. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM.
    Osteoporos Int; 2012 Nov 24; 23(11):2703-11. PubMed ID: 22297733
    [Abstract] [Full Text] [Related]

  • 13. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 14. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Wilson N, Walker S, Hartigan C, Khan N, Page M, Robinson ME, Saleh DS, Smit K, Rauch F, Siminoski K, Ward LM.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):536-548. PubMed ID: 37610420
    [Abstract] [Full Text] [Related]

  • 15. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A, Tageja M, Didwal G, Khandelwal NK, Saini AG, Saini L, Sahu JK, Dayal D, Sankhyan N.
    J Pediatr Endocrinol Metab; 2021 May 26; 34(5):573-581. PubMed ID: 33838091
    [Abstract] [Full Text] [Related]

  • 16. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, Heather N, Pitkin J, Emmanuel J, Lee KJ, Wang X, Simm PJ, Munns CF.
    J Clin Endocrinol Metab; 2021 Jul 13; 106(8):2328-2342. PubMed ID: 33954789
    [Abstract] [Full Text] [Related]

  • 17. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.
    Bianchi ML, Morandi L, Andreucci E, Vai S, Frasunkiewicz J, Cottafava R.
    Osteoporos Int; 2011 Feb 13; 22(2):529-39. PubMed ID: 20458570
    [Abstract] [Full Text] [Related]

  • 18. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov 13; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 13; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 20. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb 13; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.